MétaCan
Menu
Back to cohort
Record W4412708027 · doi:10.1016/j.esmoop.2025.105506

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer

2025· article· en· W4412708027 on OpenAlexfundno aff
Rinath Jeselsohn, Jun Fu, Yi Ren, Reshma Mahtani, X. Cynthia, A. DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D. Miller, Yara Abdou, Elizabeth C. Riley, R Qamar, Priyanka Sharma, S. Reid, Y Liu, Eric Gauthier, HJ Burstein, Mark T. DeMeo, MM Regan, Sara M. Tolaney, Erica L. Mayer

Bibliographic record

VenueESMO Open · 2025
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsnot available
FundersBristol-Myers SquibbSamsungGenentechNateraSeagenPuma BiotechnologyPfizerIncyteBeiGeneMersana TherapeuticsMenarini Silicon BiosystemsAstex PharmaceuticalsEisaiJazz PharmaceuticalsMcGill UniversityDaiichi Sankyo EuropeGilead SciencesSanofiExelixisGlaxoSmithKlineAmgenCelgeneAstraZenecaEli Lilly and Company
KeywordsFulvestrantPalbociclibMetastatic breast cancerOncologyInternal medicineCancer researchCancerBreast cancerMedicineBiologyEstrogen receptor

Abstract

fetched live from OpenAlex

BACKGROUND: Genomic determinants of response and resistance to endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer are not well characterized. We analyzed serial circulating tumor DNA from the PACE trial in which patients who progressed on ET and CDK4/6i were randomized to fulvestrant, fulvestrant plus palbociclib, or fulvestrant, palbociclib, and avelumab. MATERIALS AND METHODS: Plasma samples from 200 of 220 PACE participants were collected for circulating tumor DNA analysis using the Guardant360 assay. Samples included baseline (n = 200), cycle 3, day 1 (C3D1; n = 124), and end of treatment (n = 137). The fulvestrant and fulvestrant + palbociclib arms were combined given similar clinical outcomes. The log-rank test was used to test associations between genomic alterations and progression-free survival (PFS). RESULTS: The most common baseline genomic alterations beyond progression on CDK4/6i plus ET, were mutations in ESR1 (54.0%), TP53 (35.5%), PIK3CA (34.0%), GATA3 (18.5%), and RB1 (10.0%). Among 150 patients treated with fulvestrant or fulvestrant + palbociclib, baseline mutations in TP53, PIK3CA, RB1, and the Y537S ESR1 mutation, were associated with shorter PFS. Mutations within the PI3K and cell cycle pathways were associated with significantly decreased PFS. We also observed increases in the allelic fractions of the ESR1, PIK3CA, and TP53 mutations at progression. CONCLUSIONS: Several mutations within genes and biological pathways are associated with CDK4/6i resistance beyond progression. Additional studies are needed to optimize treatment after resistance to CDK4/6i using genomic biomarkers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.396
Threshold uncertainty score0.489

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.384
Teacher spread0.367 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207